On 22 May 2026, the European Medicines Agency (EMA) published a document titled "Questions for CVMP in relation to EMA’s recommendations under Article 107(6) and Article 114(3)", outlining queries for its Committee for Medicinal Products for Veterinary Use (CVMP). The document aims to clarify procedural aspects of EMA's recommendations concerning veterinary medicines, impacting pharmaceutical companies, national competent authorities, and veterinarians.
The document, issued by EMA's Veterinary Medicines Division, sets out specific questions for CVMP to address when EMA issues recommendations under Article 107(6) (related to referral procedures) and Article 114(3) (concerning urgent safety restrictions) of Regulation (EU) 2019/6. These articles govern how EMA can recommend changes to marketing authorisations in cases of safety concerns or other regulatory issues. The questions cover topics such as the scope of the recommendation, the evidence required, and the timeline for implementation.
As a guidance document, it is not legally binding but serves to standardise CVMP's approach, ensuring consistency in how EMA's recommendations are translated into regulatory action. The document does not set numerical targets but rather procedural expectations.
Policy orientations and trade-offs
The document reflects a balance between ensuring rapid regulatory action to protect animal and public health (under Article 114(3)) and maintaining thorough scientific evaluation (under Article 107(6)). This trade-off is typical in pharmacovigilance: speed versus depth. The questions aim to streamline decision-making without compromising safety.
Impact on stakeholders
- Pharmaceutical companies: May face clearer expectations but also tighter deadlines for implementing safety restrictions, potentially increasing compliance costs.
- National competent authorities: Benefit from harmonised procedures, reducing ambiguity in implementing EMA recommendations, but may need to adapt internal processes.
- Veterinarians and animal owners: Indirectly benefit from faster safety actions, though could face temporary shortages if products are restricted.
- CVMP members: Gain structured guidance, but may have less flexibility in interpreting recommendations.
Expected institutional follow-up
CVMP is expected to discuss the questions at its next meeting and may issue further guidance or revise its standard operating procedures. The document is part of EMA's ongoing efforts to refine the regulatory framework for veterinary medicines under the new Veterinary Regulation.